PL398796A1 - The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis - Google Patents

The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis

Info

Publication number
PL398796A1
PL398796A1 PL398796A PL39879612A PL398796A1 PL 398796 A1 PL398796 A1 PL 398796A1 PL 398796 A PL398796 A PL 398796A PL 39879612 A PL39879612 A PL 39879612A PL 398796 A1 PL398796 A1 PL 398796A1
Authority
PL
Poland
Prior art keywords
mirna
prevention
treatment
multiple sclerosis
antagomir
Prior art date
Application number
PL398796A
Other languages
Polish (pl)
Inventor
Marcin Mycko
Krzysztof Selmaj
Original Assignee
Krzysztof Selmaj
Marcin Mycko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krzysztof Selmaj, Marcin Mycko filed Critical Krzysztof Selmaj
Priority to PL398796A priority Critical patent/PL398796A1/en
Priority to PCT/EP2013/057585 priority patent/WO2013153155A2/en
Publication of PL398796A1 publication Critical patent/PL398796A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem wynalazku jest zastosowanie czasteczek niekodujacych RNA (mikroRNA) oraz antagomirów dla miRNA w medycynie, zwlaszcza w zapobieganiu i leczeniu chorób autoimmunologicznych, w szczególnosci stwardnienia rozsianego.The invention relates to the use of non-coding RNAs (microRNAs) and antagomirs for miRNAs in medicine, especially in the prevention and treatment of autoimmune diseases, in particular multiple sclerosis.

PL398796A 2012-04-11 2012-04-11 The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis PL398796A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL398796A PL398796A1 (en) 2012-04-11 2012-04-11 The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis
PCT/EP2013/057585 WO2013153155A2 (en) 2012-04-11 2013-04-11 The use of mirna particles and mirna antagomir for diagnostics, prevention and treatment of multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL398796A PL398796A1 (en) 2012-04-11 2012-04-11 The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
PL398796A1 true PL398796A1 (en) 2013-10-14

Family

ID=48669859

Family Applications (1)

Application Number Title Priority Date Filing Date
PL398796A PL398796A1 (en) 2012-04-11 2012-04-11 The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis

Country Status (2)

Country Link
PL (1) PL398796A1 (en)
WO (1) WO2013153155A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111777667B (en) * 2020-07-10 2022-09-09 上海交通大学医学院 Small peptide and application thereof in preparation of immunoregulation medicine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2290102A1 (en) * 2009-07-08 2011-03-02 Administración General De La Communidad Autónoma De Euskadi Methods for the diagnosis of multiple sclerosis based on its microRNA expression profiling
US20120064122A1 (en) * 2010-09-13 2012-03-15 David Baltimore Treatment of autoimmune inflammation using mir-155
WO2013013165A2 (en) * 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus

Also Published As

Publication number Publication date
WO2013153155A3 (en) 2013-12-05
WO2013153155A2 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
MX2021006052A (en) Complement component irna compositions and methods of use thereof.
MX2019006413A (en) Serpinc1 irna compositions and methods of use thereof.
MX2019008380A (en) Complement component c5 irna compositions and methods of use thereof.
MD20150006A2 (en) Inhibitors of the miR-15 family of micro-RNAs
EA201490563A1 (en) ANTI-SMALL OLIGONUCLEOTIDE FOR THE TREATMENT OF CONGENITAL LEAVER AMAUROSIS
HK1214179A1 (en) Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types
MX2013005875A (en) Microrna inhibitors comprising locked nucleotides.
NZ630596A (en) Methods for treatment of alport syndrome
HK1210216A1 (en) Double-stranded oligonucleotide molecules to p53 and methods of use thereof p53
WO2014022739A3 (en) Modified rnai agents
MX342927B (en) Synthetic mimics of mir-34.
UA117098C2 (en) Microrna compounds and methods for modulating mir-21 activity
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
JP2012228254A5 (en)
MX2018013216A (en) Compositions and methods for inhibiting expression of tmprss6 gene.
WO2015017675A3 (en) Methods and compounds useful in conditions related to repeat expansion
MX2016016992A (en) Aptamers specific for tlr-4 and uses thereof.
WO2015048020A3 (en) Compositions and methods for the manufacture of lipid nanoparticles
IN2014CN03921A (en)
WO2015007871A3 (en) Micrornas and autoimmune-immune mediated inflammatory disease
PL398796A1 (en) The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis
WO2011103028A3 (en) Compositions and methods for inhibiting mmset
EP2878604A4 (en) Monomer for synthesis of rna, method for producing same, and method for producing rna
WO2012014190A3 (en) Compositions and methods for prognosis of mesothelioma
MX368084B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions.